Overview

A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.

Status:
Completed
Trial end date:
2016-07-11
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and tolerability of MEDI-545 in Japanese adult SLE patients. This will be done by collecting the data from 3 cohorts of IV doses and 1 cohort of SC doses.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
MedImmune LLC
Treatments:
Antibodies, Monoclonal
Sifalimumab